Q: Both down a lot would you buy or sell
5i Research Answer:
We have mutliple comments posted on PRL. We think it is a HOLD or a buy if more weakness occurs. We do not know SLNO very well. As a small cap biotech, it has $500M cash, but no revenue, losses and negative cash flow. Soleno’s lead product, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet designed to treat hyperphagia in PWS patients. Shares plunged this week and we would see it more as sell based on negative momentum, risk, and overall growth prospects.